These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 16121317)

  • 21. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
    de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
    Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract]   [Full Text] [Related]  

  • 25. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
    Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
    Opitz CF; Ewert R; Kirch W; Pittrow D
    Eur Heart J; 2008 Aug; 29(16):1936-48. PubMed ID: 18562303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for pulmonary arterial hypertension.
    Liu C; Liu K; Ji Z; Liu G
    Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
    Kim NH; Rubin LJ
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 39. The current treatment of pulmonary arterial hypertension: time to redefine success.
    Rich S
    Chest; 2006 Oct; 130(4):1198-202. PubMed ID: 17035456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.